SCHEMBL4935290

SCHEMBL4935290

CC(=O)Nc1ccccc1-n1c(O)nnc1-c1ccc(O)cc1O.c1cc2ccc1-2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.42
KDM4E B2RXH2 2/20 0.42
APOBEC3A P31941 1/20 0.42
GFER P55789 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
HSP90AA1 P07900 5/20 0.41
TYR P14679 2/20 0.40
HDAC3 O15379 1/20 0.39
HDAC2 Q92769 1/20 0.39
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
CHEK1 O14757 1/20 0.36
LMNA P02545 1/20 0.36
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4940524 0.81 FYN (0.44) GFERNPC1MAPTALDH1A1HPGD
SCHEMBL4943310 0.76 HSP90AA1 (0.64) HSP90AA1ALDH1A1HPGDLMNA
SCHEMBL4936858 0.74 HSP90AA1 (0.60) KDM4EHSP90AA1MAPTALDH1A1HPGD
SCHEMBL4941528 0.73 HSP90AA1 (0.61) HSP90AA1
SCHEMBL4948249 0.73 ABCC1 (0.46) HDAC1KDM4EAPOBEC3AGFERAPOBEC3G
SCHEMBL931818 0.71 HSP90AA1 (0.43) HSP90AA1ALDH1A1HPGDMEN1KMT2A
SCHEMBL930881 0.69 HSP90AA1 (0.50) KDM4EHSP90AA1MAPTALDH1A1HPGD
SCHEMBL4935303 0.67 RAB9A (0.53) KDM4ETYRNPC1POLBMAPT
SCHEMBL931845 0.67 HSP90AA1 (0.43) KDM4EHSP90AA1POLBMAPTALDH1A1
SCHEMBL4939682 0.66 ESR1 (0.48) KDM4EHSP90AA1POLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US claimed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP claimed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO claimed
US-8618285-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2013-12-31 US disclosed
EP-1853570-B1 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-24 EP disclosed
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US disclosed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP disclosed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182857-A1 Triazole Derivatives HSP90AB1, HSP90AA1, HSP90B1 HDAC1 106/4885KDM4E 3777/4885APOBEC3A 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.